Drug maker Lupin on Monday said it has received approval from the US health regulator to market a generic medication for Human Immunodeficiency Virus. The company has received tentative approval from the US Food and Drug Administration for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide tablets, the company said in a statement.
The company's product has been found to be therapeutically equivalent to the reference listed drug Symtuza tablets, 800 mg/150 mg/200 mg/10 mg of Janssen Products, LP, it added.
Lupin is the exclusive first-to-file for this product, it stated.
As per the IQVIA MAT December 2024 data, Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide tablets had estimated annual sales of $1,374 million in the US.
Shares of Lupin were trading 1.29% down at Rs 2,028.70 apiece on BSE.
RECOMMENDED FOR YOU
Solution To Infertility? Scientists Create And Fertilize Eggs From Human Skin Cells
Oct 01, 2025
Cabinet Approves Rs 2,277 Crore Push For Capacity Building and Human Resource Development
Sep 24, 2025
Google Cuts 200 Jobs; Laid-Off Workers Say Fired After 'Training AI To Replace Them'
Sep 16, 2025
Lupin Gets USFDA Nod For Generic Risperidone Extended-Release Injectable Suspension
Sep 03, 2025
POPULAR
